Evidence map›Paper›PMID 36293365›Full record

ArticleInternational journal of molecular sciences2022

Sandra Smiljanic, Cyril Messaraa, Virginie Lafon-Kolb, Nina Hrapovic, Nahid Amini, Christina Osterlund, Lene Visdal-Johnsen

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. From traditional remedy toFrontiers in pharmacology · 2026
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sandra SmiljanicOriflame Cosmetics, Swedish Research & Innovation Lab, Fleminggatan 14, 112 26 Stockholm, Sweden.ORCID 0000-0002-2435-3965
Cyril MessaraaOriflame Cosmetics, R&D Ltd., Bray Business Park, Kilruddery, A98 Y6W0 Bray, Ireland.ORCID 0000-0002-4948-9949
Virginie Lafon-KolbOriflame Cosmetics, Swedish Research & Innovation Lab, Fleminggatan 14, 112 26 Stockholm, Sweden.
Nina HrapovicOriflame Cosmetics, Swedish Research & Innovation Lab, Fleminggatan 14, 112 26 Stockholm, Sweden.
Nahid AminiOriflame Cosmetics, Swedish Research & Innovation Lab, Fleminggatan 14, 112 26 Stockholm, Sweden.
Christina OsterlundOriflame Cosmetics, Swedish Research & Innovation Lab, Fleminggatan 14, 112 26 Stockholm, Sweden.
Lene Visdal-JohnsenOriflame Cosmetics, Swedish Research & Innovation Lab, Fleminggatan 14, 112 26 Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Scandinavian region is home to a unique biome with endemic plant species. The aim of this study was to explore this natural diversity and identify plant extracts providing positive skin barrier effects. Six plant extracts were identified as starting material. Following biochemical screening, two candidates outperformed the rest:

Indexed as

EricaceaePlant ExtractsAntioxidantsBetulaCyclooxygenase 2Fruit and Vegetable JuicesHumansHyaluronoglucosaminidaseNiacinamidePlant BarkAntioxidantsCyclooxygenase 2HyaluronoglucosaminidaseNiacinamidePlant ExtractsBetula albaEmpetrum nigrumhydrationnatural ingredientScandinavian endemic plantsskin barrier

Identifiers

PMID36293365
PMCPMC9604162
OpenAlexW4306835996

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.